Literature DB >> 21836500

Diffuse large B-cell lymphoma with aberrant expression of the T-cell antigens CD2 and CD7.

Nikhil A Sangle1, Archana M Agarwal, Kristi J Smock, Matthew O Leavitt, Roger Warnke, David Bahler, Sherrie L Perkins.   

Abstract

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Although, aberrant expression of a single T-cell-associated antigen (exclusive of CD5) on diffuse large B-cell lymphoma has occasionally been described in the literature, cases that show coexpression of ≥2 T-cell antigens on a well-documented case of diffuse large B-cell lymphoma are extremely rare. Here, we describe a well-characterized case of diffuse large B-cell lymphoma that showed aberrant coexpression of 2 T-cell-associated antigens, CD2 and CD7. Recognition of these types of cases is important to help ensure accurate diagnoses are made.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21836500     DOI: 10.1097/PAI.0b013e318221c672

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  4 in total

1.  Aberrant expression of multiple T cell markers on diffuse large B cell lymphoma: a case report.

Authors:  Anurag Mehta; Prerna Chadha; Poojan Agarwal; Sunil Pasricha
Journal:  J Egypt Natl Canc Inst       Date:  2021-06-15

2.  Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.

Authors:  Naoko Tsuyama; Daisuke Ennishi; Masahiro Yokoyama; Satoko Baba; Reimi Asaka; Yuko Mishima; Yasuhito Terui; Kiyohiko Hatake; Kengo Takeuchi
Journal:  Oncotarget       Date:  2017-05-16

Review 3.  Biomarkers of HIV-associated Cancer.

Authors:  Brian Thabile Flepisi; Patrick Bouic; Gerhard Sissolak; Bernd Rosenkranz
Journal:  Biomark Cancer       Date:  2014-07-03

4.  New Contributions to Asarum Powder on Immunology Related Toxicity Effects in Lung.

Authors:  Yamin Li; Lintao Han; Chunhua Huang; Wangqiang Dai; Guangyu Tian; Fang Huang; Jingjing Li; Jinwei Liu; Qiong Wang; Zhenxiang Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-02       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.